NCT00381914

Brief Summary

The research team is comprised of an expert nutrition scientist and a pediatrician with expertise in endocrinology. Both have world-class experience in assessing bone mass in infancy. Together they have designed a study to determine how much dietary vitamin D is needed to optimize health in infants. This is important since many infants are born with vitamin D deficiency. At present the dosage of vitamin D that is optimal for infant health is unclear and recent research suggests that vitamin D status very early in life has long lasting effects on bone mass and other health issues. Therefore, in a group of healthy infants, this research team will test which dosage of vitamin D is needed to achieve optimal vitamin D status. Optimal vitamin D status will be based on growth, biomarkers of vitamin D and bone status in blood and also general health. The infants will all be breastfed and begin the study at about 2 weeks of age. At 3 months intervals over the first year of life, each infant will be measured for growth, duration of breastfeeding and supplement use plus have a bone density scan to determine changes in bone growth. The data will be helpful to guide health care professionals in providing the best care possible for their infants. It will also be important to the health of populations since dietary recommendations for vitamin D are used to guide fortification of foods and development of evidence based policy around nutrient recommendations and their implementation.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
132

participants targeted

Target at P75+ for phase_2

Timeline
Completed

Started Mar 2007

Longer than P75 for phase_2

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 27, 2006

Completed
1 day until next milestone

First Posted

Study publicly available on registry

September 28, 2006

Completed
5 months until next milestone

Study Start

First participant enrolled

March 1, 2007

Completed
4.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2011

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2011

Completed
Last Updated

March 2, 2012

Status Verified

March 1, 2012

Enrollment Period

4.5 years

First QC Date

September 27, 2006

Last Update Submit

March 1, 2012

Conditions

Keywords

InfantsVitamin DDose-response

Outcome Measures

Primary Outcomes (1)

  • Vitamin D plasma concentrations

    25(OH)D concentrations will me measured in infants over the first year of life. The blood sampling will be done at 1, 2, 3, 6, 9 and 12 months of age. Monitoring the vitamin D concentrations will allow the investigators to determine the best dose of vitamin D for breast fed infants receiving one of three vitamin D dosages.

    12 months

Secondary Outcomes (1)

  • Bone mineral content

    12 months

Study Arms (3)

1

EXPERIMENTAL

400 IU / day vitamin D

Drug: Vitamin D

2

EXPERIMENTAL

800 IU / day vitamin D

Drug: Vitamin D

3

EXPERIMENTAL

1200 IU / day vitamin D

Drug: Vitamin D

Interventions

400 IU vitamin D / day

1

Eligibility Criteria

Age2 Weeks - 5 Weeks
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17)

You may qualify if:

  • Healthy singleton term born infants of appropriate size for gestational age (AGA) according to the Centers for Disease Control growth charts based on weight at birth between the 5th and 95th percentiles for sex; and born to healthy breastfeeding women. This allows us to assess growth and bone mineral accretion without bias of intrauterine growth restriction.

You may not qualify if:

  • Infants of mothers with history of gestational diabetes or hypertension in pregnancy; chronic alcohol use; malabsorption syndromes due to malabsorption of vitamin D (celiac disease, Crohn's etc.); and multiple births.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Mary Emily Clinical Nutrition Research Unit

Sainte-Anne-de-Bellevue, Quebec, H9X 2E3, Canada

Location

Related Publications (5)

  • Gharibeh N, Gallo S, Sotunde OF, Vanstone CA, Rodd CJ, Weiler HA. Patterns of Bone Mineral Accretion and Sex Differences in Healthy Term Vitamin D Replete and Breastfed Infants From Montreal, Canada: Bone Mass Reference Data. J Clin Densitom. 2022 Jan-Mar;25(1):43-53. doi: 10.1016/j.jocd.2021.07.004. Epub 2021 Jul 24.

  • Huey SL, Acharya N, Silver A, Sheni R, Yu EA, Pena-Rosas JP, Mehta S. Effects of oral vitamin D supplementation on linear growth and other health outcomes among children under five years of age. Cochrane Database Syst Rev. 2020 Dec 8;12(12):CD012875. doi: 10.1002/14651858.CD012875.pub2.

  • Mok E, Vanstone CA, Gallo S, Li P, Constantin E, Weiler HA. Diet diversity, growth and adiposity in healthy breastfed infants fed homemade complementary foods. Int J Obes (Lond). 2017 May;41(5):776-782. doi: 10.1038/ijo.2017.37. Epub 2017 Feb 6.

  • Hazell TJ, Gallo S, Berzina I, Vanstone CA, Rodd C, Weiler HA. Plasma 25-hydroxyvitamin D, more so than its epimer, has a linear relationship to leaner body composition across infancy in healthy term infants. Appl Physiol Nutr Metab. 2014 Oct;39(10):1137-43. doi: 10.1139/apnm-2013-0586. Epub 2014 May 1.

  • Gallo S, Comeau K, Vanstone C, Agellon S, Sharma A, Jones G, L'Abbe M, Khamessan A, Rodd C, Weiler H. Effect of different dosages of oral vitamin D supplementation on vitamin D status in healthy, breastfed infants: a randomized trial. JAMA. 2013 May 1;309(17):1785-92. doi: 10.1001/jama.2013.3404.

MeSH Terms

Conditions

Vitamin D Deficiency

Interventions

Vitamin D

Condition Hierarchy (Ancestors)

AvitaminosisDeficiency DiseasesMalnutritionNutrition DisordersNutritional and Metabolic Diseases

Intervention Hierarchy (Ancestors)

SecosteroidsSteroidsFused-Ring CompoundsPolycyclic Compounds

Study Officials

  • Hope A Weiler, PhD

    McGill University

    PRINCIPAL INVESTIGATOR
  • Celia Rodd, MD

    Montreal Children's Hospital of the MUHC

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor

Study Record Dates

First Submitted

September 27, 2006

First Posted

September 28, 2006

Study Start

March 1, 2007

Primary Completion

September 1, 2011

Study Completion

December 1, 2011

Last Updated

March 2, 2012

Record last verified: 2012-03

Locations